Collection
Neuroendocrine Tumors: Here is the future of nuclear medicine
Neuroendocrine tumors have increased in incidence in recent decades, constituting a highly diverse neoplasms predominantly characterized by the expression of somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has emerged as a pivotal strategy for addressing advanced, unresectable neuroendocrine tumors. This involves the intravenous administration of radiolabeled somatostatin analogs to specifically target SSTRs. The present collection focuses on the multidisciplinary theranostic approach of PRRT in neuroendocrine patients within various clinical contexts. Topics covered will include the efficacy of treatment, dosimetric considerations, patient outcomes, and the overall patient journey. Additionally, we will offer insights into the future landscape of this therapeutic modality, exploring promising new radiopharmaceuticals, including those utilizing alpha-emitting radionuclides.
Editors
-
Dr. Chiara Maria Grana
Divisione Medicina Nucleare, IRCCS Istituto Europeo di Oncologia, Milan, Italy
-
Dr. Laura Lavinia Travaini
Divisione Medicina Nucleare, IRCCS Istituto Europeo di Oncologia, Milan, Italy
